Postprandial Period Clinical Trial
Official title:
Effect of Drinks Containing Fruit Polyphenol Extracts and Fibre on Postprandial Glycaemia. The Glu-MIX Study
NCT number | NCT03572296 |
Other study ID # | HVS-010 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 25, 2018 |
Est. completion date | January 28, 2019 |
Verified date | January 2019 |
Source | Lucozade Ribena Suntory |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postprandial glycaemia refers to the transient rise in blood glucose levels that occurs after
consuming a meal. Large fluctuations in blood glucose levels, experienced on a frequent
basis, may impair the functioning of pancreatic beta cells, and thus elevate the risk of
developing type 2 diabetes mellitus (T2DM) and cardiovascular disease. Our group has
previously shown that consuming a drink containing fruit polyphenols immediately before a
meal, may reduce postprandial glycaemia. Importantly, other fruit components, namely soluble
fibres, also impact on carbohydrate digestion by slowing gastric emptying rates. Combining
fruit polyphenols and fibre in a drink may, potentially, have additive or synergistic effects
on reducing postprandial glycaemia.
This study will investigate the effects of drinks containing blackcurrant polyphenol extract
combined with pulp (source of fibre), and pulp alone, on postprandial outcomes and cognitive
function following a mixed carbohydrate (starch and sucrose) test meal.
Status | Completed |
Enrollment | 38 |
Est. completion date | January 28, 2019 |
Est. primary completion date | January 28, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age: 18-70 years - Men and women - Healthy (free of diagnosed diseases listed in the exclusion criteria) - Body Mass Index 18-35 kg/m2 - Able to understand the information sheet and willing to comply with study protocol - Able to give informed written consent Exclusion Criteria: - Those diagnosed with Phenylketonuria (PKU) - Those with known or suspected food intolerances, allergies or hypersensitivity - Women who are known to be pregnant or who are intending to become pregnant over the course of the study - Women who are breastfeeding - Participation in another clinical trial - Those who have donated blood within 3 months of the screening visit and participants for whom participation in this study would result in having donated more than 1500 millilitres of blood in the previous 12 months. - Full Blood Counts and Liver Function test results outside of the normal range. - Current smokers, or reported giving up smoking within the last 6 months - History of substance abuse or alcoholism - Reported history of Cardiovascular disease, diabetes (or fasting glucose = 7.1 mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of drug likely to alter gastrointestinal function - Unwilling to restrict consumption of specified high polyphenol/ high fibre foods for 48 h before the study - Weight change >3 kg in preceding 2 months - Blood pressure =160/100 mmHg - Total cholesterol = 7.5 mmol/L; fasting triacylglycerol concentrations = 5.0 mmol/L - Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose: Glucobay), insulin sensitizing drugs (metformin: Glucophage, Glucophage SR, Eucreas, Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron, Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid lowering drugs (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates). Other medications should be reviewed by medical representative from KCL on a case by case basis. - Nutritional supplements that may interfere with the study: higher dose vitamins/minerals (>200% Recommend Nutrient Intake), B vitamins, Vitamin C, calcium, copper, chromium, iodine, iron, magnesium, manganese, phosphorus, potassium and zinc. Subjects already taking vitamin or minerals at a dose around 100% or less up to 200% of the RNI, or evening primrose/algal/fish oil supplements will be asked to maintain habitual intake patterns, ensuring that they take them every day and not sporadically. They will be advised not to stop taking supplements or start taking new supplements during the course of the study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Metabolic Research Unit | London |
Lead Sponsor | Collaborator |
---|---|
Lucozade Ribena Suntory | King's College London |
United Kingdom,
Castro-Acosta ML, Smith L, Miller RJ, McCarthy DI, Farrimond JA, Hall WL. Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations. J Nutr Biochem. 2016 Dec;38:154-161. doi: 10.1016/j.jnutbio.2016.09.002. Epub 2016 Sep 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 7-d food diary (estimated/unweighed) | Habitual dietary intake analysis | 7-days | |
Other | 100 mm visual analogue scale (VAS) measures of the palatability of the study drink | For each VAS, a numerical score between 0 (not at all) and 100 (extremely) mm was obtained. | 10 min following the test drink | |
Other | 100 mm visual analogue scale (VAS) measures of mood, satiety and digestive comfort | For each VAS, a numerical score between 0 (not at all) and 100 (extremely) mm was obtained. | 150 min | |
Other | Ad libitum energy intake | Energy intake during ad libitum meal | 15 min | |
Other | 100 mm visual analogue scale (VAS) measures of the palatability of the ad libitum meal | For each VAS, a numerical score between 0 (not at all) and 100 (extremely) mm was obtained. | 15 min following the ad libitum meal | |
Other | Buccal mouth swab | Future exploratory analysis of lactase activity via the derived allele at the European | One off sample, collected at the first 1 day of study visit | |
Primary | Postprandial glycaemia (iAUC 0-30 min) | The primary endpoint is iAUC 0-30 min for plasma glucose concentrations | 30 min | |
Secondary | Postprandial glycaemia: iAUC 0-120 min | iAUC 0-120 min for plasma glucose concentrations | 120 min | |
Secondary | Postprandial glycaemia: iAUC 0-150 min | iAUC 0-150 min for plasma glucose concentrations | 150 min | |
Secondary | Postprandial glycaemia: iCmax | iCmax for plasma glucose concentrations | 150 min | |
Secondary | Postprandial glycaemia: Tmax | Tmax for plasma glucose concentrations | 150 min | |
Secondary | Postprandial glycaemia: absolute concentrations at specific time points | Absolute concentrations at specific time points, for plasma glucose concentrations | 150 min | |
Secondary | Postprandial insulinemia: iAUC 0-30 min | iAUC 0-30 min for serum insulin concentrations | 30 min | |
Secondary | Postprandial insulinemia: iAUC 0-120 min | iAUC 0-120 min for serum insulin concentrations | 120 min | |
Secondary | Postprandial insulinemia: iAUC 0-150 min | iAUC 0-150 min for serum insulin concentrations | 150 min | |
Secondary | Postprandial insulinemia: iCmax | iCmax, for serum insulin concentrations | 150 min | |
Secondary | Postprandial insulinemia: Tmax | Tmax for serum insulin concentrations | 150 min | |
Secondary | Postprandial insulinemia: absolute concentrations at specific time points | Absolute concentrations at specific time points, for serum insulin concentrations | 150 min | |
Secondary | Postprandial C-peptide: iAUC 0-30 min | iAUC 0-30 min for plasma C-peptide concentrations | 30 min | |
Secondary | Postprandial C-peptide: iAUC 0-120 min | iAUC 0-120 min for plasma C-peptide concentrations | 120 min | |
Secondary | Postprandial C-peptide: iAUC 0-150 min | iAUC 0-150 min for plasma C-peptide concentrations | 150 min | |
Secondary | Postprandial C-peptide: iCmax | iCmax for plasma C-peptide concentrations | 150 min | |
Secondary | Postprandial C-peptide: Tmax | Tmax for plasma C-peptide concentrations | 150 min | |
Secondary | Postprandial C-peptide: Absolute concentrations at specific time points | Absolute concentrations at specific time points, for plasma C-peptide concentrations | 150 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-30 min | iAUC 0-30 min for plasma GIP concentrations | 30 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-120 min | iAUC 0-120 min for plasma GIP concentrations | 120 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-150 min | iAUC 0-150 min for plasma GIP concentrations | 150 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): iCmax | iCmax, for plasma GIP concentrations | 150 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): Tmax | Tmax for plasma GIP concentrations | 150 min | |
Secondary | Postprandial blood glucose-dependent insulinotropic peptide (GIP): Absolute concentrations at specific time points | Absolute concentrations at specific time points, for plasma GIP concentrations | 150 min | |
Secondary | Cognitive function test scores | Descriptive statistics | Before and after 150 min blood collection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03184064 -
Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia
|
N/A | |
Completed |
NCT03994276 -
The Postprandial Effects of Chick-Pea Consumption on Glucose, Insulin, and Gut Hormone Responses (PEA-POD).
|
N/A | |
Completed |
NCT01618071 -
Vascular Effects of Triglyceride-rich Lipoproteins
|
N/A | |
Recruiting |
NCT06231706 -
ZOE BIOME Study: Biotics Influence on Microbiome Ecosystem
|
N/A | |
Completed |
NCT04989478 -
Postprandial Metabolism in Healthy Young Subjects
|
N/A |